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Abstract
Background—Converging evidence points to the involvement of γ-amino-butyric acid B
receptors (GABABRs) in the regulation of information processing. We previously showed that
GABABR agonists exhibit antipsychotic-like properties in rodent models of sensorimotor gating
deficits, as measured by the prepulse inhibition (PPI) of the acoustic startle reflex. The therapeutic
potential of these agents, however, is limited by their neuromuscular side effects; thus, in the
present study we analyzed whether rac-BHFF, a potent GABABR positive allosteric modulator
(PAM), could counter spontaneous and pharmacologically induced PPI deficits across various
rodent models.
Methods—We tested the antipsychotic effects of rac-BHFF on the PPI deficits caused by the N-
methyl-D-aspartate glutamate receptor antagonist dizocilpine, in Sprague-Dawley rats and
C57BL/6 mice. Furthermore, we verified whether rac-BHFF ameliorated the spontaneous PPI
impairments in DBA/2J mice.
Results—rac-BHFF dose-dependently countered the PPI deficits across all three models, in a
fashion akin to the GABABR agonist baclofen and the atypical antipsychotic clozapine; in contrast
with these compounds, however, rac-BHFF did not affect startle magnitude.
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Conclusions—The present data further support the implication of GABABRs in the modulation
of sensorimotor gating, and point to their PAMs as a novel promising tool for antipsychotic
treatment, with fewer side effects than GABABR agonists.
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Introduction
Ample evidence shows that γ-amino-butyric acid (GABA), the main inhibitory
neurotransmitter in the CNS, is implicated in schizophrenia pathogenesis [1-3]. In particular,
several clinical investigations have documented deficits in the expression of the
metabotropic GABAB receptors (GABABRs) in the cortex and hippocampus of
schizophrenia patients [4-6]. The mechanisms supporting the involvement of GABABRs in
psychotic disorders remain elusive; however, recent findings suggest that the dysfunction of
this receptors in the cortex leads to alterations of glutamate signaling and excitatory/
inhibitory imbalances [7-8], which contribute to the aberrant information processing and
cognitive deficits in schizophrenia [9-10].
In keeping with this background, our group and others showed that the prototypical
GABABR agonist baclofen (BAC) countered the disruption of prepulse inhibition (PPI) of
the acoustic startle reflex produced by the blockade of N-methyl-D-aspartate glutamate
receptors (NMDARs) in rats [11-12] and mice [13]. This endophenotype is widely regarded
as a heuristic index of sensorimotor gating, the cognitive function that enables pre-
attentional information filtering and governs the detection of perceptual salience [14];
notably, PPI deficits are featured in schizophrenia and related neuropsychiatric disorders
[15-16].
In subsequent studies, we found that BAC rescued the marked deficits in sensorimotor
gating present in DBA/2J mice [17], a strain that features antipsychotic-sensitive PPI deficits
[18].
These findings collectively highlight GABABR as a highly promising target for
antipsychotic treatment. Indeed, Daskalakis and George [19] hypothesized that GABABR
activation may be the mechanism underlying the unique ability of the antipsychotic agent
clozapine (CLO) in reducing the severity of negative symptoms in schizophrenia. While
BAC monotherapy does not elicit significant antipsychotic effects [20], preliminary studies
have documented its therapeutic effectiveness as an adjunctive treatment [21-22]. The
therapeutic employment of BAC in schizophrenia is limited by several factors, including its
poor ability to cross the blood-brain barrier, its short latency of action [23], as well as its
potentially severe side effects, including muscle flaccidity, sedation, loss of reflexes, and, at
higher dosages, bradycardia, respiratory depression, hypothermia and coma [24]. A new
class of GABABR positive allosteric modulators (PAMs) has been recently developed [25]
to harness the therapeutic potential of GABABR activation without eliciting the side effects
of BAC. The mechanism of these compounds is based on the enhancement of the effects of
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GABA on GABABRs [26-27]. One of the most potent drugs in this family, rac-BHFF
[(R,S)-5,7-di-tert-butyl-3-hydroxy-3-trifluoromethyl-3H-benzofuran-2-one] [25], has been
shown to produce behavioral effects without altering motor coordination and nervous
reflexes, and with a much better safety index than GABABR agonists [25; 28-31]. Here we
show that rac-BHFF elicited antipsychotic-like effects on the pharmacologically induced
and spontaneous gating deficits in rodent models, as assessed through the paradigm of the
prepulse inhibition (PPI) of the acoustic startle reflex; although these effects were
comparable to those of BAC and CLO, rac-BHFF did not induce the same alterations of
startle reflex associated with these drugs.
Materials and methods
Animals
We used behaviorally-naïve male Sprague-Dawley rats weighing between 250-300 g, and
male DBA/2J and C57BL/6J between 18-24 g. Animals were housed 4/cage in a room
maintained at a temperature of 22°C and kept under an artificial 12/12-h light/dark cycle.
Animals were given ad libitum access to food and water and handled for 5 min daily to
minimize experimental stress. All experimental procedures were approved by the ethical
committee of the University of Cagliari and carried out in strict accordance with the
guidelines for experimental animals care [European Economic Community (86/609; DL
27/01/92, number 110)].
Drugs
rac-BHFF (Hoffmann-La Roche, Basel, Switzerland) was suspended in a mixture containing
Cremophor EL, 1,2-propanediol and distilled water (4:1:30 ratio) and administered
intragastrically (per os, PO) at an injection volume of 10 ml/kg. The NMDAR antagonist
dizocilpine (DIZ; Sigma-Aldrich, Milan, Italy) was dissolved in 0.9% saline and
administered subcutaneously (SC). BAC (Tocris Cookson, Bristol, UK) was dissolved in
saline and administered intraperitoneally (IP). CLO (Sigma-Aldrich) was dissolved in a
single drop of 1 N HCl and diluted with saline; the pH was adjusted to 7 with NaHCO3.
Parenteral injections were administered in injection volumes of 1 ml/kg for rats and 10ml/kg
for mice.
Experimental procedures
Acoustic startle reflex and PPI were measured in 4 sound-attenuated chambers (Med
Associates, St Albans, USA) with fan ventilation. Each chamber consisted of a Plexiglas
cylinder (9 cm diameter for rats and 3.2 cm diameter for mice) mounted on a piezoelectric
accelerometric platform and connected to an analogue-digital converter. Background noise
and acoustic bursts were conveyed by two separate speakers, properly spaced from the
cylinder so as to produce a variation of sound within 1 dB across it. Both speakers and
startle cylinders were connected to a main PC computer, which detected and analyzed all
chamber variables by means of specific software. Before every testing session, acoustic
stimuli and mechanical responses were calibrated via specific devices supplied by Med
Associates.
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The experimental procedure was based on the protocols described in Frau et al [32]. Briefly,
three days before the experiment, animals went through a brief baseline startle session.
Animals were exposed to 70 dB background white noise for a 5 min acclimation, followed
by presentation to a randomized sequence of twelve 40 ms acoustic pulses of 115 dB,
interposed with three trials in which an 82 dB prepulse preceded the 115 dB pulse by 100
ms. Subsequently, treatment groups were established so that average startle responses and %
PPI (calculated as: 100-[(mean startle amplitude for prepulse+pulse trials/mean startle
amplitude for pulse alone trials) × 100]) were equivalent across groups. On the testing day,
each animal was placed in the cylinder for a 5-min acclimation to 70 dB background white
noise, which continued for the remainder of the entire session. The session consisted of three
consecutive blocks of trials. Unlike the first and the third block, during which animals were
presented with only five pulse-alone trials of 115 dB, the second block displayed a
pseudorandom sequence of 50 trials, including 12 pulse-alone trials, 30 trials of pulse
preceded by 74, 78 or 86 dB prepulses (ten for each level of prepulse loudness) and eight no
stimulus trials, where only background noise was delivered. Intertrial intervals (ITI) were
selected randomly between 10 and 15 s. The duration of pulses and prepulses were 40 and
20 ms, respectively. Prepulse-pulse delay amounted to 100 ms.
Data analysis
Normality and homoscedasticity of data were verified by Kolmogorov-Smirnov and
Bartlett's tests. Data were compared across groups by one-way or two-way ANOVAs, as
appropriate. As no interaction between prepulse levels and treatment were found in the
statistical analysis, %PPI values were collapsed across prepulse intensity to represent
average %PPI. Post-hoc analyses were performed using Tukey's test with Spjøtvoll-Stoline
correction. Significance threshold was set at 0.05.
Results
Effects of rac-BHFF on the PPI deficits induced by DIZ in Sprague Dawley rats
In the first experiment, we investigated whether rac-BHFF pretreatment could prevent the
PPI disruption induced by the NMDAR antagonist DIZ in Sprague Dawley rats. Animals
were pretreated with either rac-BHFF (25-50 mg/kg, PO) or vehicle (control) and sixty
minutes later were given an injection of either DIZ (0.1 mg/kg, SC) or saline (control).
Animals were subjected to PPI testing five min after the last treatment.
No significant differences in startle amplitude were found between pretreatment-treatment
groups (Fig. 1A) [Interaction: F2,47=0.10; NS]. Conversely, we found a significant
pretreatment × treatment interaction (Fig. 1B) [Interaction: F2,47=4.62, P<0.05] between
groups. Post-hoc analyses revealed that the highest dose of rac-BHFF significantly reversed
DIZ-induced PPI deficits (P<0.05; Tukey's test).
In contrast, BAC (5 mg/kg, IP) produced a significant reduction in startle amplitude [Main
effect: F1,37=9.44; P<0.01] (Fig.1A); furthermore, it significantly prevented the PPI
impairments caused by DIZ [Interaction: F1,37=4.89; P<0.05; P<0.05 for vehicle-DIZ vs
BAC-DIZ comparisons] (Fig. 1B). As expected, CLO (5 mg/kg, IP) elicited similar effects,
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with a general reduction of startle magnitude [Main effect: F1,37=7.17; P<0.05] (Fig.1A) and
a significant reversal of DIZ-mediated PPI deficits [Interaction: F1,37=5.27; P<0.05; P<0.05
for vehicle-DIZ vs CLO-DIZ comparisons] (Fig. 1B).
Effects of rac-BHFF on the PPI deficits induced by DIZ in C57BL/6J mice
Next, we studied whether rac-BHFF (6.25-12.5 mg/kg, PO) exhibited antipsychotic-like
effects in C57BL/6J mice treated with DIZ (0.3mg/kg, IP). In parallel with our results on
rats, no differences were found between groups for startle amplitude (Fig. 2A) [Interaction:
F2,59 = 1.99, NS]; however, we detected a marked pretreatment × treatment interaction (Fig.
2B) [F2,52=5.32, P<0.01]. Specifically, the PPI-disruptive effects of DIZ (P<0.01) were
prevented by rac-BHFF treatment at a dose of 12.5mg/kg (P<0.001; Tukey's test). As
previously shown [17], BAC (5 mg/kg, IP) did not affect startle amplitude in C57BL/6J
mice (Fig.2A); notably, the PPI analysis indicated main effects for both pre-treatment
(BAC) [F1,41=7.00; P<0.05] and treatment (DIZ) [F1,41=8.13; P<0.01], but no significant
interactions [F1,41=2.32; NS] (Fig. 2B). Conversely, CLO (5 mg/kg, IP) reduced startle
magnitude [Main effect: F1,41=7.84; P<0.01] (Fig.2A) and significantly countered the PPI
disruption induced by DIZ [Interaction: F1,41=4.81; P<0.05; P<0.05 for vehicle-DIZ vs
CLO-DIZ comparisons] (Fig. 2B).
Effects of rac-BHFF on the spontaneous PPI deficit displayed by DBA/2J strain of mice
In the last experiment we evaluated the intrinsic effects of rac-BHFF on the spontaneous
low PPI baseline displayed by DBA/2J mice. Animals were treated with VEH or rac-BHFF
(6.25-12.5 mg/kg, PO) and subjected to PPI sessions sixty minutes later. The GABABR
PAM did not elicit any changes in startle amplitude at any dose (Fig. 3A) [F2,35=0.99, NS].
In contrast, low PPI in DBA mice was countered by rac-BHFF [F2,35=4.63 P<0.05)],
specifically at the dose of 12.5 mg/kg (P<0.05; Tukey's test) (Fig. 3B). BAC and CLO failed
to affect startle amplitude, but significantly countered DIZ-induced PPI deficits [BAC:
F1,20=10.28; P<0.01; CLO: F1,20=12.36; P<0.01] (Fig. 3B).
Discussion
The results of this study showed that rac-BHFF, a potent GABABR PAM, dose-dependently
reversed DIZ-induced PPI deficits in both SD rats and C57BL/6J mice, and rescued the PPI
impairments displayed by DBA/2J mice. Overall, these effects were akin to those elicited by
the GABABR agonist BAC and the atypical antipsychotic CLO, and substantially confirm
previous findings by our group and others [11-13; 18] on the therapeutic potential of
GABABR activators on sensorimotor gating deficits induced by NMDAR blockade.
Notably, in contrast with BAC and CLO, rac-BHFF did not significantly reduce the
magnitude of startle reflex, irrespective of the animal model and dose. It is also worth
mentioning that the same doses of rac-BHFF that elicited antipsychotic-like effects in our
models also failed to affect locomotor responses or other spontaneous behavioral
manifestations in the home cage [unpublished observations]. Taken together, our findings
complement previous preclinical data on the beneficial effects of GABABR PAMs [33-34]
and highlight this class of compound as a novel putative avenue for antipsychotic therapy
with fewer side effects than GABABR antagonists.
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One of the key problems in the potential employment of BAC as an add-on treatment lies in
the exacerbation of locomotor impairments and sedative effects caused by dopamine D2
receptor antagonism; indeed, in preliminary studies we observed that the association of BAC
and antipsychotic drugs, such as CLO and haloperidol, was not suitable for behavioral
studies in rodents, in view of the serious impairments in neuromuscular coordination
produced by such combinations. From this perspective, GABABR PAMs may afford a safer
and tolerable alternative as antipsychotic adjunctive therapies for schizophrenia or related
disorders. Future clinical and preclinical studies are warranted to evaluate this interesting
perspective and validate the potential usefulness of rac-BHFF and similar agents in the
treatment of psychoses.
The PPI of the acoustic response refers to the reduction in the response amplitude to a
sudden and intense startling stimulus [pulse], when it is immediately preceded by a weaker
non-startling pre-stimulus [35]. This phenomenon is widely regarded as a dependable index
of sensorimotor gating integrity, and is typically impaired in schizophrenia [17]. In rodents,
DIZ and other NMDAR antagonists produce marked PPI deficits, which are sensitive to
CLO and other atypical, but not typical, antipsychotics [36-38]. The effects of NMDAR
antagonists on sensorimotor gating are in line with the well-known psychotomimetic effects
of these drugs [39] and other alterations of informational processing [40].
Although the mechanisms by which DIZ and other NMDAR blockers impair PPI remain
unclear, several studies point to a key role of the prefrontal cortex (PFC) and hippocampal
regions in these phenomena [12; 41]. These areas are characterized by a large density of pre-
and postsynaptic GABABRs, which finely regulate basal glutamatergic and dopaminergic
functions [42]. Accordingly, disturbances in GABABR expression or function may affect
informational salience by altering the inhibitory/excitatory balance of several
neurotransmitter systems in corticolimbic regions.
It has been reported that MK-801 and PCP stimulate cortical glutamate release in PFC and
hippocampus [43]. In this scenario, rac-BHFF could counteract the disinhibition of neuronal
activity produced by exaggerated NMDAR stimulation in these areas or, alternatively,
modulate distinct forebrain pathways under the control of non-NMDA glutamatergic
receptors, such as AMPA and Kainate [44]. Alternatively, rac-BHFF may counter DIZ-
mediated PPI-deficits by acting on the pallidotegmental nucleus (PTn). This predominantly
GABAergic area exhibits high levels of GABABRs and acts as an interface between the
brainstem and forebrain regions implicated in PPI regulation regions [45]. Accordingly, DIZ
has been recently shown to induce PPI deficits through alterations of the giant neurons of
this region; notably, GABABR activation reversed these impairments by stabilizing the
hyperactivation of these nuclei [13].
rac-BHFF also significantly ameliorated the PPI deficits on DBA/2J mice, a strain
characterized by spontaneous gating impairments sensitive to antipsychotics [19], as well as
other phenotypes reminiscent of schizophrenia symptoms, such as poor exploration as well
as high aggression and social avoidance [46-49].
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The antipsychotic-like actions of rac-BHFF in this murine strain may be related to their
reduced expression of GABABRs and NMDARs across the cortex and hippocampus, in
comparison with C57BL/6J mice [18; 50].
Several limitations in the present study should be acknowledged. First, our analysis was
limited to the behavioral analysis of startle reflex and PPI, but did not include the testing of
other paradigms with great relevance to the negative and cognitive symptoms of
schizophrenia-spectrum disorders, such as object recognition and social interaction test
[51-52]. Second, we did not evaluate the effects of rac-BHFF in animal models with high
translational validity with respect to schizophrenia, such as DISC1- and neuregulin1-
deficient mice, or rodents subjected to chronic administration of DIZ or other NMDAR
antagonists, which may have better simulated the neurobiological impairments associated
with schizophrenia [53-58]. Third, our research did not encompass testing of GABAB
negative allosteric modulators or antagonists, which may be essential for a full definition of
the role of these receptors in schizophrenia-related endophenotypes.
Although further investigations are needed to address these limitations, our findings extend
and support for the role of GABABRs in the pathophysiology of psychiatric disorders
associated with sensorimotor gating disturbances, and point to PAMs of these targets as
interesting therapeutic tools to treat cognitive deficits and negative symptoms in
schizophrenia.
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Effects of rac-BHFF on the mean startle amplitude (A) and prepulse inhibition deficits (B)
induced by dizocilpine (DIZ, 0.1 mg/kg, SC) in Sprague Dawley rats, compared to baclofen
and clozapine. All doses are given in milligrams per kilogram and are indicated below the
horizontal axis. Values represent mean ± SEM for each treatment. Percent prepulse
inhibition (PPI) values were collapsed across all three prepulse intensities (4, 8, and 16 dB
above 70 dB background noise). For all experimental groups, n=8-12. SAL, saline. ***,
P<0.001, compared to VEH+SAL group; #, P<0.05, compared to VEH+DIZ group. For
further details, see text.
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Effects of rac-BHFF on the mean startle amplitude (A) and spontaneously low prepulse
inhibition deficits (B) induced by dizocilpine (DIZ, 0.3 mg/kg, IP) in C57BL/6J mice,
compared to baclofen and clozapine. All doses are given in milligrams per kilogram and are
indicated below the horizontal axis. Values represent mean ± SEM for each treatment.
Percent prepulse inhibition (PPI) values were collapsed across all three prepulse intensities
(4, 8, and 16 dB above 70 dB background noise). For all experimental groups, n=8-12. SAL,
saline. **, P<0.01, compared to VEH+SAL group; ###, P<0.001, #, P<0.05, compared to
VEH+DIZ group. For further details, see text.
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Effects of rac-BHFF on the mean startle amplitude (A) and spontaneous prepulse inhibition
deficits (B) displayed by DBA/2J mice, compared to baclofen and clozapine. All doses are
given in milligrams per kilogram and are indicated below the horizontal axis. Values
represent mean ± SEM for each treatment. Percent prepulse inhibition (PPI) values were
collapsed across all three prepulse intensities (4, 8, and 16 dB above 70 dB background
noise). For all experimental groups, n=8-10. **, P<0.01, compared to VEH group. For
further details, see text.
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